STAMFORD, Conn., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company will be participating in the following upcoming investor conferences:
- Citi Annual Biotech Conference on September 6, 2017 in Boston. At 1:00 PM ET, Joshua H. Bilenker, M.D., chief executive officer, will be participating in a panel discussion entitled, “Precision Medicine in Oncology and Next Generation Diagnostics.”
- Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. At 4:40 PM ET, Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview.
Live webcasts of the panel and presentation will be available at http://ir.loxooncology.com/.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
jake@loxooncology.com
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com
Media:
Dan Budwick
1AB Media
973-271-6085
dan@1abmedia.com